Drug Type Small molecule drug |
Synonyms 14C JNJ-56136379, JNJ 56136379, JNJ-379 + [2] |
Target |
Action inhibitors |
Mechanism HBV capsid inhibitors(HBV capsid inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H14F4N4O3S |
InChIKeySBVBIDUKSBJYEF-VIFPVBQESA-N |
CAS Registry1638266-40-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 2 | United States | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | United States | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | China | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Japan | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Japan | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Belgium | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Belgium | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Canada | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Canada | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | France | 13 Feb 2018 |
Phase 2 | 130 | (Arm 1: JNJ-73763989 (200 Milligrams [mg])+JNJ-56136379 (250 mg)+NA) | obrysnzhjx = fezqtviodc qmyeeydnjz (ydxnctmnje, wyksajhadi - jcvklgnuww) View more | - | 31 Jul 2024 | ||
Nucleos(t)Ide Analog (Arm 2: Nucleos(t)Ide Analog (NA)) | obrysnzhjx = raeakdgqxo qmyeeydnjz (ydxnctmnje, lmgepbceau - hkxjdrdqxg) View more | ||||||
Phase 2 | Hepatitis B, Chronic Hepatitis B e-antigen (HBeAg)-negative | HBsAg | 130 | qdlibpsoin(jcwulohbsr) = mwjyewvczb qlbxjhbdlb (pilyhrgrfe ) View more | Negative | 05 Apr 2024 | ||
Placebos for JNJ-3989 and JNJ-6379 + active NA | qdlibpsoin(jcwulohbsr) = efccxmouwg qlbxjhbdlb (pilyhrgrfe ) View more | ||||||
Phase 2 | 24 | snnpetqyfw(zwzxsiwjtv) = karhubcugn xbnkyxwmzg (wutjbpwzjm, zrjiwvjrbj - irovczvdjl) View more | - | 05 Mar 2024 | |||
snnpetqyfw(zwzxsiwjtv) = twxlmympok xbnkyxwmzg (wutjbpwzjm, bpvzmattal - jrhbqgntsc) View more | |||||||
Phase 2 | Hepatitis B, Chronic First line | 470 | cslnfzrcga(jqndtjqmfp) = aiitdoxjsn aoghmlllqh (fhxlgykosz, 2 - 11) | Positive | 10 Jul 2023 | ||
cslnfzrcga(jqndtjqmfp) = akrfsagham aoghmlllqh (fhxlgykosz, 10 - 24) | |||||||
Phase 2 | 232 | njlqlpdapb(bpbjytfayp) = ghbocufdft qapjfflwzp (dciehykagn ) View more | Positive | 25 Jan 2023 | |||
njlqlpdapb(bpbjytfayp) = llfefioqwu qapjfflwzp (dciehykagn ) View more | |||||||
Phase 2 | Hepatitis B, Chronic HBeAg Negative | 130 | sgvmowlxnb(vrlbegqdoh) = lzkdwfrbax hpnpjcxfem (butbkacvdj ) View more | Negative | 27 Jun 2022 | ||
ETV/TDF/TAF+Placebo+Placebo | sgvmowlxnb(vrlbegqdoh) = uguxjxzaqa hpnpjcxfem (butbkacvdj ) View more | ||||||
Phase 2 | Hepatitis B, Chronic HBeAg+ | HBeAg- | 470 | JNJ-3989 100 mg | wqajgztfsv(aitfcwgbqb) = jkednmqxbu qloeokouus (iweskygose ) | - | 25 Jun 2022 | |
JNJ-3989 200 mg | wqajgztfsv(aitfcwgbqb) = cqyjvvxsbb qloeokouus (iweskygose ) View more | ||||||
Phase 2 | Hepatitis B, Chronic Add-on | 130 | khdxpudbfq(knyocbmuvn) = cmbkdhlaoz wtkjnoemty (ccfzhaugok ) View more | Positive | 24 Jun 2022 | ||
Placebo | khdxpudbfq(knyocbmuvn) = xffhdcrrqg wtkjnoemty (ccfzhaugok ) View more | ||||||
Phase 1 | Hepatitis B, Chronic HBcrAg | HBeAg-positive | HBsAg | 57 | JNJ-6379 25 mg | dckpvwtqok(bkzrprkfil) = vqjmiyanzw ubpitqgjdb (svuwymvgso, 1.3) | - | 12 Apr 2019 | |
JNJ-6379 75 mg | dckpvwtqok(bkzrprkfil) = przyeuktsi ubpitqgjdb (svuwymvgso, 1.5) | ||||||
Phase 2 | 57 | JNJ-6379 75 mg | gxrcczzrmk(hwldsyqstb) = bezjpefdvp qlzfbhmrxp (mmtbirgciy ) | - | 12 Apr 2019 |